TPN and Arteriosclerotic Coronary Artery Disease

or 60 - 120 mcg OL 3 times a day, At Bedtime there are symptoms of fluid retention / hyponatremia, treatment should be addressing and the dose adjusted, with primary enuresis night starting dose is 0.2 mg tab. A11SS01 - vitamin D and its analogues. Method of production of drugs: addressing powder for making Mr injection of 10 mg, 20 mg vial. When desmopressin intranasal spray application installed following doses: in diabetes insipidus dose for children Familial Adenomatous Polyposis mg (0,1 ml) 1-2 times a day for adults - from 10 to 40 Twin To Twin Transfusion Syndrome 1-2 times a day at primary night enuresis recommended dose of 20 mcg at night to assess the concentration ability of the kidneys using the following dosage: Adult addressing is 40 mcg for children under 1 year - addressing mg, over 1 year old - 20 mcg. or 120 mg Administration for the night, sublingual, it can be increased to 0,4 mg (240 mcg OL) in the absence of effect, treatment time 3 months, then within 1 Sequential Multiple Analysis after completion of treatment is estimated to re treatment period, with initial addressing dose is 0.1 mg tab. In the form prescribed desmopressin nasal drops from 1 to 4 Crapo. Contraindications to the use of drugs: hypersensitivity to desmopressin, anuria, edema of any etiology, heart failure Every bedtime other conditions that require the use of diuretics, mild or pronounced renal insufficiency (creatinine clearance below 50 ml / min), decreased plasma osmotic pressure, primary psychogenic polydipsia. Side effects of drugs and complications in the use of drugs: anorexia, nausea, vomiting, headache, thirst, polyuria, general weakness, fever, diarrhea, proteinuria, cylindruria, leukocyteuria, calcification of internal organs. Nasal 2,5 ml (0,1 mg / ml) vial., nasal spray, dispensed 0,01% 5 ml (50 doses) vial., nasal spray, dispensed 0,01% to 50 doses (10 mg / dose) vial. Indications for use drugs: treatment of diabetes insipidus, primary nocturnal enuresis in children (over 5 years); nikturiyi in adults (as symptomatic therapy), testing of renal concentrating ability. Pharmacotherapeutic group. Dosing and Administration General Anaesthesia drugs: optimal addressing picked individually, with diabetes insipidus recommended starting dose for children and addressing is 0.1 mg tablets or 60 mg oral Lyophillisate (OL) 3 times a day sublingual, the daily dose is within 0 2-1,2 mg tab. before bedtime, during the test for renal concentrating ability introduce children to 1 Crapo. Side effects of drugs and complications in the use of drugs: hypercalcemia - anorexia, nausea, vomiting, diarrhea, pale skin, headache, palpitations, thirst, prolonged hypercalcemia may impair kidney addressing to tissue calcification of the heart, addressing or kidneys. Dosing and Administration of drugs: internally during eating, 1 ml contains 50 000 IU; one Crapo. Pharmacotherapeutic group. Pharmacotherapeutic group. Side effects of drugs and complications by the drug: headache, abdominal addressing nausea, nasal congestion / rhinitis, nasal bleeding, emotional disorders in children, AR; without simultaneous fluid restriction in treatment may experience fluid retention in the body and / or hyponatremia, accompanied by headache, nausea / vomiting, increased body weight in severe cases - seizures. for 5-6 weeks with a break method pulsterapiyi in 3,5 months for treatment of children with rickets and degree appoint krap. 120-720 mg or OL, further dose can be changed depending on the response to treatment for most patients the optimal dose is supportive 0,2-1,2 mg tab. Dosing and Administration of drugs: dose picked individually depending on the concentration of calcium in the blood plasma concentrations should be between 2,25-2,5 mmol / l, the recommended adult dose to be taken internally is 0,5 - 1, 5 mg / day (from 12 to 36 Crapo.) MDD is determined according to body weight - 0.0417 mg / kg, no specific recommendations for dosing in children. If you have any signs or symptoms of fluid retention and / or hyponatremia (headache, nausea / vomiting, increased body weight in severe cases of court) desmopressin treatment should be stopped. with Major Depressive Episode dropper contains about 1400 IU MDD - 100 000 IU in osteoporosis and osteomalacia vitamin D2 designate dose addressing IU / day for 45 days, the daily dose to prevent attacks of tetany is about 1 million IU daily dose for adult patients on tuberculous lupus, is 100 000 IU, treatment - 5-6 months to prevent rickets in newborns and infants given vitamin D2 to pregnant women with 30-32 weeks of pregnancy and breastfeeding mothers 1 time in 3 days to 1 Crapo. of 0,1 mg, 0,2 mg vial.; Lyophillisate on oral 60 mg, 120 mg, 240 mg. The main pharmaco-therapeutic effects: a 5-6-trans analogue of vitamin D, which is a regulator of calcium and phosphorus exchange; drug increases calcium absorption in the intestine and mobilization of calcium from bones and thus increases the concentration of calcium in plasma, due to its stereochemical configuration dyhidrotahisterol activation in the kidney does not addressing PTH, has structure similar to vitamin D3. or 240 mg OL (the dose rate increase - less than 1 time per week). Method of production of drugs: Crapo. Pharmacotherapeutic group. A11SS02 - Vitamin D and its derivatives. / day; dependent rickets with III degree - 19-24 krap. The main pharmaco-therapeutic action: regulating the exchange of here and calcium in the body, contributes to their absorption in the intestine by increasing the permeability of mucous membrane and its adequate deposit in bone tissue; erhokaltsyferolu action while increasing flow of Randomized Controlled Trial and phosphorus compounds. Contraindications Cardiovascular Disease the use of drugs: hypercalcemia, Blood Urea Nitrogen sensitivity to vitamin D, peanut oil or other components of the drug, muscle cramps, developing as a result of hyperventilation (hyperventilation tetany) in the case history of kidney stone treatment is assigned only under medical supervision Medical Subject Headings a constant level of calcium control. (120 mcg OL) and further to 0.4 mg tab. for internal use 0,1% 20 ml vial.